GlassScriptPhysician profile
David F Chang
NPI 1316966138
$217,438.55
in general payments reported to CMS, 2019-2025
24 companies · $99K in 2025
The $99K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38K · 2020: $26K · 2021: $15K · 2022: $9,731 · 2023: $18K · 2024: $12K · 2025: $99K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $65K · Consulting Fee: $60K · Food and Beverage: $2,249 · Travel and Lodging: $1,295 · Entertainment: $250 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $65,283.14 |
| Consulting Fee | $60,387.50 |
| Food and Beverage | $2,249.30 |
| Travel and Lodging | $1,295.43 |
| Entertainment | $250.00 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $73,449.23 | 2021-2025 | Rxsight Injector Cartridge, Rxsight Injector Handpiece, Rxsight Contact Lens |
| Carl Zeiss Meditec, INC. | $36,375.18 | 2019-2023 | Visumax, Quatera 700, Veracity Surgical |
| Alcon Vision LLC | $32,908.99 | 2019-2025 | Unity, Acrysof Iq Vivity, Clareon |
| Alcon Research LLC | $31,316.44 | 2022-2025 | Acrysof Iq Vivity, Acrysof Iq Panoptix Uv Iol, Viscoat |
| Johnson & Johnson Surgical Vision, INC. | $27,849.05 | 2019-2025 | Compact Intuitiv, Catalys System, Healon Duet Pro |
| Ivantis, INC | $12,189.07 | 2019-2021 | |
| Cipla USA INC. | $1,200.00 | 2021 | |
| Sun Pharmaceutical Industries INC. | $504.28 | 2019-2022 | |
| Carl Zeiss Meditec USA, INC. | $478.77 | 2021-2024 | Iolmaster 700, Quatera 700, Callisto Eye |
| Kala Pharmaceuticals, INC. | $335.22 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $221.30 | 2022-2023 | Stellaris, Prolensa |
| Beaver-Visitec International, INC. | $85.92 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.62 | 2023-2025 | Jardiance |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $72.87 | 2025 | |
| Oyster Point Pharma, INC. | $56.23 | 2023-2024 | Tyrvaya |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $55.88 | 2019 | |
| Allergan, INC. | $51.26 | 2021-2022 | |
| Johnson & Johnson Vision Care, INC. | $46.89 | 2024 | Tecnis Simplicity |
| Biotissue Holdings INC. | $42.01 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $39.57 | 2020 | |
| Abbvie INC. | $24.20 | 2022 | |
| Eyepoint US, INC. | $23.41 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $18.26 | 2020 | |
| Ocular Therapeutix, INC. | $17.90 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$10,296,901.64 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.